More Chiome Bioscience Inc. news
Chiome Bioscience Inc.TSE: 4583

Supplementary Information for Financial Results Q3 FY12/26

Nov 10, 2026 at 2:00 AM EST · Issued by Chiome Bioscience Inc. via TDnet

Filed with TSE · Nov 10, 2026 at 2:00 AM EST · 44 pages · English

On 6ix: 6ix.com/news/supplementary-information-for-financial-results-q3-fy1226

Chiome Bioscience Inc. on 6ix

Earlier from Chiome Bioscience

  • Non-Consolidated Financial Results (Japanese GAAP) for the Six Months Ended June 30,2026Aug 13
  • Announcement of target-specific research and option agreement with Heidelberg PharmaJul 13, 2022
  • Service agreement with option contract with Rohto Pharmaceutical Co., Ltd.Jul 11, 2022
  • First patient in of cancer therapeutic antibody CBA-1535 in a Phase 1 clinical trialJul 4, 2022
  • Conclusion of contract with additional institutes and first dosing of CBA-1205 in the second part of Phase 1 studyJun 13, 2022
All Chiome Bioscience news releases↗

Follow Chiome Bioscience into a list and get an email when it puts out news.

Follow Chiome Bioscience
  • About 6ix
  • Editorial & Sourcing
  • Corrections
  • Contact
  • Privacy
  • Terms
  • Disclaimer